Ute KrÃ¼gel

List of Publications by Year
in descending order

83	3,958	109321	123424
papers	citations	35 h-index	61 g-index

85	85	85	4926
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Role of TRPC6 in kidney damage after acute ischemic kidney injury. Scientific Reports, 2022, 12, 3038.	3.3	7
2	A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS. International Journal of Molecular Sciences, 2022, 23, 3635.	4.1	0
3	Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity. Microbiome, 2022, 10, .	11.1	32
4	In Vivo Inhibition of TRPC6 by SH045 Attenuates Renal Fibrosis in a New Zealand Obese (NZO) Mouse Model of Metabolic Syndrome. International Journal of Molecular Sciences, 2022, 23, 6870.	4.1	6
5	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Pharmaceuticals, 2021, 14, 259.	3.8	3
6	Roux-en-Y gastric bypass contributes to weight loss-independent improvement in hypothalamic inflammation and leptin sensitivity through gut-microglia-neuron-crosstalk. Molecular Metabolism, 2021, 48, 101214.	6.5	20
7	Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 36, 102403.	3.3	16
8	Editorial: Obesogenic Environmental Conditions Affect Neurodevelopment and Neurodegeneration. Frontiers in Neuroscience, 2021, 15, 724503.	2.8	0
9	Nutraceuticals in mental diseases â€" Bridging the gap between traditional use and modern pharmacology. Current Opinion in Pharmacology, 2021, 61, 62-68.	3.5	1
10	Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth. Cancers, 2020, 12, 2707.	3.7	6
11	Gastric bypass surgery in a rat model alters the community structure and functional composition of the intestinal microbiota independently of weight loss. Microbiome, 2020, 8, 13.	11.1	40
12	Editorial: Extreme Eating Behaviours. Frontiers in Psychiatry, 2020, 11, 639219.	2.6	2
13	Studies towards the development of a PET radiotracer for imaging of the P2Y1 receptors in the brain: synthesis, 18F-labeling and preliminary biological evaluation. European Journal of Medicinal Chemistry, 2019, 165, 142-159.	5.5	12
14	Intraneural Injection of ATP Stimulates Regeneration of Primary Sensory Axons in the Spinal Cord. Journal of Neuroscience, 2018, 38, 1351-1365.	3.6	27
15	Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine, 2018, 10, .	12.4	76
16	Gastric Bypass Surgery Recruits a Gut PPAR-Î±-Striatal D1R Pathway to Reduce Fat Appetite in Obese Rats. Cell Metabolism, 2017, 25, 335-344.	16.2	108
17	Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. Pain, 2017, 158, 856-867.	4.2	63
18	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. International Journal of Molecular Sciences, 2017, 18, 768.	4.1	10

#	Article	IF	Citations
19	Pilocarpine-Induced Status Epilepticus Increases the Sensitivity of P2X7 and P2Y1 Receptors to Nucleotides at Neural Progenitor Cells of the Juvenile Rodent Hippocampus. Cerebral Cortex, 2016, 27, bhw178.	2.9	35
20	Lack of functional P2X7 receptor aggravates brain edema development after middle cerebral artery occlusion. Purinergic Signalling, 2016, 12, 453-463.	2.2	20
21	Purinergic receptors in psychiatric disorders. Neuropharmacology, 2016, 104, 212-225.	4.1	69
22	Suppressed Fat Appetite after Roux-en-Y Gastric Bypass Surgery Associates with Reduced Brain Î¼-opioid Receptor Availability in Diet-Induced Obese Male Rats. Frontiers in Neuroscience, 2016, 10, 620.	2.8	15
23	Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models. PLoS ONE, 2016, 11, e0156468.	2.5	57
24	Differential effects of Roux-en-Y gastric bypass surgery on brown and beige adipose tissue thermogenesis. Metabolism: Clinical and Experimental, 2015, 64, 1240-1249.	3.4	18
25	Impaired Cognition after Stimulation of P2Y1 Receptors in the Rat Medial Prefrontal Cortex. Neuropsychopharmacology, 2015, 40, 305-314.	5.4	28
26	Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimerâ€™s Disease Like Tau Aggregation. Vaccines, 2014, 2, 601-623.	4.4	12
27	Astrocyteâ€“neuron interaction in the substantia gelatinosa of the spinal cord dorsal horn via P2X7 receptorâ€mediated release of glutamate and reactive oxygen species. Glia, 2014, 62, 1671-1686.	4.9	51
28	The impact of social isolation on immunological parameters in rats. Archives of Toxicology, 2014, 88, 853-5.	4.2	48
29	Acute systemic rapamycin induces neurobehavioral alterations in rats. Behavioural Brain Research, 2014, 273, 16-22.	2.2	37
30	Deletion of the cell adhesion adaptor protein vinculin disturbs the localization of GFAP in Bergmann glial cells. Glia, 2013, 61, 1067-1083.	4.9	3
31	Amygdaloid Signature of Peripheral Immune Activation by Bacterial Lipopolysaccharide or Staphylococcal Enterotoxin B. Journal of NeuroImmune Pharmacology, 2013, 8, 42-50.	4.1	35
32	Flavanones That Selectively Inhibit TRPM3 Attenuate Thermal Nociception In Vivo. Molecular Pharmacology, 2013, 84, 736-750.	2.3	107
33	Antidepressant effects of TNF-Î± blockade in an animal model of depression. Journal of Psychiatric Research, 2013, 47, 611-616.	3.1	89
34	Neurobehavioural activation during peripheral immunosuppression. International Journal of Neuropsychopharmacology, 2013, 16, 137-149.	2.1	24
35	Stress-induced cytokine changes in rats. European Cytokine Network, 2013, 24, 97-103.	2.0	84
36	Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms. Neuropsychopharmacologia Hungarica, 2013, 15, 206-13.	0.1	13

#	Article	IF	Citations
37	Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nature Communications, 2012, 3, 1329.	12.8	369
38	Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B. Proceedings of the Royal Society B: Biological Sciences, 2011, 278, 1864-1872.	2.6	25
39	Dose-dependent emetic effects of the Amaryllidaceous alkaloid lycorine in beagle dogs. Toxicon, 2011, 57, 117-124.	1.6	38
40	Acute amygdaloid response to systemic inflammation. Brain, Behavior, and Immunity, 2011, 25, 1384-1392.	4.1	88
41	Purinergic signalling: From normal behaviour to pathological brain function. Progress in Neurobiology, 2011, 95, 229-274.	5.7	357
42	Reduced Food Intake and Body Weight in Mice Deficient for the G Protein-Coupled Receptor GPR82. PLoS ONE, 2011, 6, e29400.	2.5	21
43	The P2 Receptor Antagonist PPADS Supports Recovery from Experimental Stroke In Vivo. PLoS ONE, 2011, 6, e19983.	2.5	43
44	In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. Archives of Toxicology, 2011, 85, 1565-1573.	4.2	23
45	Rodent Cortical Astroglia Express In Situ Functional P2X7 Receptors Sensing Pathologically High ATP Concentrations. Cerebral Cortex, 2011, 21, 806-820.	2.9	77
46	Endogenous purinergic signaling is required for osmotic volume regulation of retinal glial cells. Journal of Neurochemistry, 2010, 112, 1261-1272.	3.9	49
47	P2Y1 receptors inhibit long-term depression in the prefrontal cortex. Neuropharmacology, 2010, 59, 406-415.	4.1	34
48	P2 receptorâ€mediated stimulation of the PI3â€K/Aktâ€pathway in vivo. Glia, 2009, 57, 1031-1045.	4.9	66
49	Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology, 2009, 204, 627-639.	3.1	33
50	Targeting murine heart and brain: visualisation conditions for multi-pinhole SPECT with 99mTc- and 123I-labelled probes. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1495-1509.	6.4	12
51	Blockade of glutamate transporters leads to potentiation of NMDA receptor current in layer V pyramidal neurons of the rat prefrontal cortex via group II metabotropic glutamate receptor activation. Neuropharmacology, 2008, 55, 447-453.	4.1	7
52	P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain. Current Medicinal Chemistry, 2007, 14, 2429-2455.	2.4	74
53	Involvement of P2X and P2Y receptors in microglial activation in vivo. Purinergic Signalling, 2007, 3, 435-445.	2.2	42
54	Changes in purinergic signaling after cerebral injury â€“ involvement of glutamatergic mechanisms?. International Journal of Developmental Neuroscience, 2006, 24, 123-132.	1.6	59

#	Article	IF	Citations
55	Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats. European Journal of Neuroscience, 2006, 23, 2824-2828.	2.6	53
56	Enhanced food intake after stimulation of hypothalamic P2Y1receptors in rats: modulation of feeding behaviour by extracellular nucleotides. European Journal of Neuroscience, 2006, 24, 2049-2056.	2.6	51
57	P2 receptors and neuronal injury. Pflugers Archiv European Journal of Physiology, 2006, 452, 622-644.	2.8	151
58	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radical Biology and Medicine, 2006, 40, 779-790.	2.9	53
59	Expression of purinergic receptors in the hypothalamus of the rat is modified by reduced food availability. Brain Research, 2006, 1089, 143-152.	2.2	33
60	Modulation of feeding behaviour by blocking purinergic receptors in the rat nucleus accumbens: a combined microdialysis, electroencephalographic and behavioural study. European Journal of Neuroscience, 2004, 19, 396-404.	2.6	27
61	P2 receptors are involved in the mediation of motivation-related behavior. Purinergic Signalling, 2004, 1, 21-29.	2.2	26
62	4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models. Biochemical and Biophysical Research Communications, 2004, 323, 979-986.	2.1	23
63	Purinergic modulation of extracellular glutamate levels in the nucleus accumbens in vivo. International Journal of Developmental Neuroscience, 2004, 22, 565-570.	1.6	24
64	P2 receptor-mediated effects on the open field behaviour of rats in comparison with behavioural responses induced by the stimulation of dopamine D2-like and by the blockade of ionotrophic glutamate receptors. Behavioural Brain Research, 2004, 149, 197-208.	2.2	7
65	Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. European Journal of Pharmacology, 2003, 482, 185-187.	3.5	147
66	Chronic food restriction alters purinergic receptor mRNA expression in the nucleus accumbens of the rat. Drug Development Research, 2003, 59, 95-103.	2.9	12
67	Immunoreactivity for glial fibrillary acidic protein and P2 receptor expression on astrocytes in vivo. Drug Development Research, 2003, 59, 175-189.	2.9	9
68	Purinergic modulation of neuronal activity in the mesolimbic dopaminergic system in vivo. Synapse, 2003, 47, 134-142.	1.2	65
69	Stimulation of P2Y1 Receptors Causes Anxiolytic-like Effects in the Rat Elevated Plus-maze: Implications for the Involvement of P2Y1 Receptor-Mediated Nitric Oxide Production. Neuropsychopharmacology, 2003, 28, 435-444.	5.4	61
70	The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4â€™-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. Neuroscience, 2001, 102, 241-243.	2.3	37
71	P2X receptor expression on astrocytes in the nucleus accumbens of rats. Neuroscience, 2001, 108, 421-429.	2.3	109
72	Deafferentation of the septo-hippocampal pathway in rats as a model of the metabolic events in Alzheimer's disease. International Journal of Developmental Neuroscience, 2001, 19, 263-277.	1.6	35

#	Article	IF	Citations
73	Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. Neuropharmacology, 2001, 40, 1084-1093.	4.1	54
74	P2 receptors on macroglial cells: Functional implications for gliosis. Drug Development Research, 2001, 53, 140-147.	2.9	11
75	Mechanisms of adenosine 5?-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo. Synapse, 2001, 39, 222-232.	1.2	54
76	P2 receptor-types involved in astrogliosis in vivo. British Journal of Pharmacology, 2001, 134, 1180-1189.	5.4	93
77	Accelerated functional recovery after neuronal injury by P2 receptor blockade. European Journal of Pharmacology, 2001, 420, R3-R4.	3.5	14
78	Suppression of feeding-evoked dopamine release in the rat nucleus accumbens by the blockade of P2 purinoceptors. European Journal of Pharmacology, 2000, 406, R13-R14.	3.5	16
79	Effects of intra-accumbens injection of 2-methylthio ATP: a combined open field and electroencephalographic study in rats. Psychopharmacology, 2000, 150, 123-131.	3.1	26
80	P2 receptor-mediated proliferative effects on astrocytes in vivo. Glia, 1999, 28, 190-200.	4.9	102
81	Adenosine 5â€²-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo. Neuroscience Letters, 1999, 265, 49-52.	2.1	50
82	Chapter 18 P2 receptor-mediated activation of noradrenergic and dopaminergic neurons in the rat brain. Progress in Brain Research, 1999, 120, 223-235.	1.4	14
83	Deciphering the functional role of host-microbiota interactions on metabolic health induced by Roux-en-Y gastric bypass (RYGB) surgery. Endocrine Abstracts, 0, , .	0.0	0